Title:
EZH2 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC SUBSTANCES THEREOF, AND APPLICATION OF EZH2 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/206155
Kind Code:
A1
Abstract:
The present invention provides an EZH2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of the EZH2 inhibitor. Specifically, the present invention provides N-((4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-yl)methyl)-5-ethyl-4-(ethyl((1S,4S)-4-(3-methyl azacyclobutanazine-1-yl)cyclohexyl)amino)-1-methyl-1H-indazol-6-formamide or polymorphic substances of pharmaceutically acceptable salts thereof, and application of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-yl)methyl)-5-ethyl-4-(ethyl((1S,4S)-4-(3-methyl azacyclobutanazine-1-yl)cyclohexyl)amino)-1-methyl-1H-indazol-6-formamide. In addition, also disclosed are a pharmaceutical composition containing the inhibitor and application thereof.
Inventors:
JIANG TAOTAO (CN)
ZHAO SHUANGNI (CN)
LI JINJING (CN)
YAO XIA (CN)
ZHAO SHUANGNI (CN)
LI JINJING (CN)
YAO XIA (CN)
Application Number:
PCT/CN2019/083971
Publication Date:
October 31, 2019
Filing Date:
April 23, 2019
Export Citation:
Assignee:
SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
International Classes:
C07D231/56; A61K31/397; A61K31/416; A61K31/4439; A61P11/00; A61P19/08; A61P31/12; A61P35/00; C07D403/14
Domestic Patent References:
| WO2018086592A1 | 2018-05-17 | |||
| WO2015104677A1 | 2015-07-16 | |||
| WO2017035060A1 | 2017-03-02 |
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: